281 related articles for article (PubMed ID: 33478888)
1. Cellular therapy for the treatment of solid tumors.
Grimes JM; Carvajal RD; Muranski P
Transfus Apher Sci; 2021 Feb; 60(1):103056. PubMed ID: 33478888
[TBL] [Abstract][Full Text] [Related]
2. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead.
Kirtane K; Elmariah H; Chung CH; Abate-Daga D
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301811
[TBL] [Abstract][Full Text] [Related]
3. Adoptive CD8
Jiang X; Xu J; Liu M; Xing H; Wang Z; Huang L; Mellor AL; Wang W; Wu S
Cancer Lett; 2019 Oct; 462():23-32. PubMed ID: 31356845
[TBL] [Abstract][Full Text] [Related]
4. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
5. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
6. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
Jindal V; Arora E; Gupta S
Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies.
Springuel L; Lonez C; Alexandre B; Van Cutsem E; Machiels JH; Van Den Eynde M; Prenen H; Hendlisz A; Shaza L; Carrasco J; Canon JL; Opyrchal M; Odunsi K; Rottey S; Gilham DE; Flament A; Lehmann FF
BioDrugs; 2019 Oct; 33(5):515-537. PubMed ID: 31363930
[TBL] [Abstract][Full Text] [Related]
8. Making CAR T Cells a Solid Option for Solid Tumors.
Schmidts A; Maus MV
Front Immunol; 2018; 9():2593. PubMed ID: 30467505
[TBL] [Abstract][Full Text] [Related]
9. Adoptive T cell therapy for solid tumors: current landscape and future challenges.
Albarrán V; San Román M; Pozas J; Chamorro J; Rosero DI; Guerrero P; Calvo JC; González C; García de Quevedo C; Pérez de Aguado P; Moreno J; Cortés A; Soria A
Front Immunol; 2024; 15():1352805. PubMed ID: 38550594
[TBL] [Abstract][Full Text] [Related]
10. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
11. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.
Srivastava S; Riddell SR
J Immunol; 2018 Jan; 200(2):459-468. PubMed ID: 29311388
[TBL] [Abstract][Full Text] [Related]
13. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.
Long KB; Young RM; Boesteanu AC; Davis MM; Melenhorst JJ; Lacey SF; DeGaramo DA; Levine BL; Fraietta JA
Front Immunol; 2018; 9():2740. PubMed ID: 30559740
[TBL] [Abstract][Full Text] [Related]
14. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
[TBL] [Abstract][Full Text] [Related]
15. Improving the efficacy and safety of engineered T cell therapy for cancer.
Shi H; Liu L; Wang Z
Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
[TBL] [Abstract][Full Text] [Related]
16. Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead.
Soltantoyeh T; Akbari B; Karimi A; Mahmoodi Chalbatani G; Ghahri-Saremi N; Hadjati J; Hamblin MR; Mirzaei HR
Cells; 2021 Jun; 10(6):. PubMed ID: 34207884
[TBL] [Abstract][Full Text] [Related]
17. [Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].
Zhou SY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):490-492. PubMed ID: 30060355
[TBL] [Abstract][Full Text] [Related]
18. Reprogramming the tumor microenvironment to enhance adoptive cellular therapy.
Beavis PA; Slaney CY; Kershaw MH; Gyorki D; Neeson PJ; Darcy PK
Semin Immunol; 2016 Feb; 28(1):64-72. PubMed ID: 26611350
[TBL] [Abstract][Full Text] [Related]
19. CAR-T cell and Personalized Medicine.
Cruz-Ramos M; García-Foncillas J
Adv Exp Med Biol; 2019; 1168():131-145. PubMed ID: 31713169
[TBL] [Abstract][Full Text] [Related]
20. Adoptive T-Cell Therapy for Solid Malignancies.
Jafferji MS; Yang JC
Surg Oncol Clin N Am; 2019 Jul; 28(3):465-479. PubMed ID: 31079800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]